更新于：2024-12-14
Tolfenamic Acid
托芬那酸
更新于：2024-12-14
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 丹麦 (2000-06-06), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C14H12ClNO2 |
InChIKeyYEZNLOUZAIOMLT-UHFFFAOYSA-N |
CAS号13710-19-5 |
关联
2
项与 托芬那酸 相关的临床试验A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Tolfenamic Acid for the Treatment of Progressive Supranuclear Palsy
09.017 - A Phase I Study of Tolfenamic Acid With Gemcitabine and Radiation in Patients With Locally Advanced or Metastatic Pancreatic Cancer Requiring Definitive or Palliative Radiation Therapy
100 项与 托芬那酸 相关的临床结果
登录后查看更多信息
100 项与 托芬那酸 相关的转化医学
登录后查看更多信息
100 项与 托芬那酸 相关的专利（医药）
登录后查看更多信息
410
项与 托芬那酸 相关的文献（医药）2024-11-01VETERINARY ANAESTHESIA AND ANALGESIA
Perioperative pain management in dogs and cats: Attitudes and practices among Thai veterinarians
Article
作者: Mama, Khursheed ; Niyom, Sirirat ; Thunpattranon, Teerapat ; Lekchareonsuk, Chalermpon ; Kasemsuwan, Suwicha
OBJECTIVE:
To assess attitudes of Thai veterinarians towards perioperative pain management in dogs and cats, and explore associations between demographic characteristics and use of analgesics and pain assessment.
STUDY DESIGN:
Paper-based survey distributed in person during various small animal practitioner conferences in 2022.
METHODS:
The questionnaire encompassed six sections: demographic information, use of analgesic techniques, postoperative pain evaluation, pain indicators, general opinions and confidence in managing postoperative pain in dogs and cats. Chi-square test, logistic regression model and Mann-Whitney U or Kruskal-Wallis tests were used for data analysis; p < 0.05 was considered significant.
RESULTS:
A total of 390 completed questionnaires were collected, with one discarded owing to potential erroneous responses. The most widely used analgesics were alpha-2 adrenergic receptor agonists (84%), postoperative non-steroidal anti-inflammatory drugs (NSAIDs; 83.5%) and preoperative opioids (74.3%). Carprofen (87.3%) and tolfenamic acid (80.9%) were the most frequently administered NSAIDs, while tramadol (86%) and morphine (71%) were the most widely used opioids. Preoperative and postoperative opioid administration were less common among males than females, with odds ratios (ORs) of 0.53 and 0.56, respectively (both p = 0.009). Veterinarians who graduated after 2014 were less likely to prescribe preoperative NSAIDs than those who graduated before 2009 (OR = 0.25; p < 0.001). Epidural anesthesia, nerve blocks and pre- and postincisional blocks were more frequently used by referral center veterinarians than those working in non-referral clinics (ORs = 30.5, 14.7, 4.29 and 8.85, respectively; all p < 0.001) and by veterinarians holding advanced degrees beyond the Doctor of Veterinary Medicine (DVM) compared with those with a DVM degree (OR = 6.25, 4.83, 2.25 and 5.75, respectively; all p < 0.001).
CONCLUSIONS AND CLINICAL RELEVANCE:
This study reveals variations in perioperative pain management practices in dogs and cats among veterinarians, influenced by sex, graduation year, education and workplace.
2024-11-01Veterinary Medicine and Science
Plasma and Milk Pharmacokinetics and Estimated Milk Withdrawal Time of Tolfenamic Acid in Lactating Sheep
Article
作者: Durna Corum, Duygu ; Elmas, Muammer ; Uney, Kamil ; Cetin, Gul ; Coskun, Devran ; Corum, Orhan
ABSTRACT:
Objective:
This study aimed to investigate the plasma and milk pharmacokinetics, as well as the withdrawal time (WT) from milk of tolfenamic acid (2 and 4 mg/kg) following intravenous (IV) administration to eight healthy lactating Akkaraman sheep.
Methods:
The trial was conducted in two periods in accordance with a crossover pharmacokinetic design. The concentrations of tolfenamic acid in the plasma and milk were determined using high‐pressure liquid chromatography and evaluated using non‐compartmental analysis. The WT of tolfenamic acid in milk was calculated using the WT 1.4 software.
Results:
Compared to the 2 mg/kg dose, plasma volume of distribution at steady state (from 0.43 to 0.50 L/kg), terminal elimination half‐life (from 2.41 to 4.14 h) and dose‐normalized area under the plasma concentration–time curve (AUC0−∞, from 9.46 to 30.11 h µg/mL) increased, whereas total body clearance (from 0.21 to 0.13 L/h/kg) decreased at the 4 mg/kg dose. The peak milk concentration (Cmax) and AUC0−∞ values in milk were 0.26 µg/mL and 0.28 h µg/mL, respectively, for 2 mg/kg, and 0.43 µg/mL and 0.55 h µg/mL, respectively, for 4 mg/kg. Although the dose‐normalized Cmax of milk decreased depending on the dose, no difference was observed in dose‐normalized AUC0−∞. The AUC0−∞ milk/AUC0−∞ plasma ratio was 0.03 for 2 mg/kg and 0.02 for 4 mg/kg. The WT values calculated for milk at dosages of 2 and 4 mg/kg were 3 and 4 h, respectively.
Conclusions:
A decrease in plasma elimination and an increase in plasma concentration of tolfenamic acid were observed depending on the dose. Tolfenamic acid lowly passed into sheep's milk at 2 and 4 mg/kg doses. This study may provide valuable information for clinicians’ decision‐making processes.
2024-07-01Veterinary Medicine and Science
Pharmacokinetics, bioavailability and plasma protein binding of tolfenamic acid in rainbow trout (Oncorhynchus mykiss)
Article
作者: Acar, Omer Faruk ; Durna Corum, Duygu ; Aksoy, Mert ; Marin, Pedro ; Uney, Kamil ; Corum, Orhan
Abstract:
Background:
Although research on the mechanism and control of pain and inflammation in fish has increased in recent years, the use of analgesic drugs is limited due to the lack of pharmacological information about analgesic drugs. Tolfenamic acid is a non‐steroidal anti‐inflammatory drug and can be used in fish due to its low side effect profile and superior pharmacokinetic properties.
Objectives:
The pharmacokinetics, bioavailability and plasma protein binding of tolfenamic acid were investigated following single intravascular (IV), intramuscular (IM) and oral administration of 2 mg/kg in rainbow trout at 13 ± 0.5°C.
Methods:
The experiment was carried out on a total of 234 rainbow trout (Oncorhynchus mykiss). Tolfenamic acid was administered to fish via IV, IM and oral route at a dose of 2 mg/kg. Blood samples were taken at 13 different sampling times until the 72 h after drug administration. The plasma concentrations of tolfenamic acid were quantified using high pressure liquid chromatography–ultraviolet (UV) and pharmacokinetic parameters were assessed using non‐compartmental analysis.
Results:
The elimination half‐life (t1/2ʎz) of tolfenamic acid for IV, IM and oral routes was 3.47, 6.75 and 9.19 h, respectively. For the IV route, the volume of distribution at a steady state and total body clearance of tolfenamic acid were 0.09 L/kg and 0.03 L/h/kg, respectively. The peak plasma concentration and bioavailability for IM and oral administration were 8.82 and 1.24 µg/mL, and 78.45% and 21.48%, respectively. The mean plasma protein binding ratio of tolfenamic acid in rainbow trout was 99.48% and was not concentration dependent.
Conclusions:
While IM route, which exhibits both the high plasma concentration and bioavailability, can be used in rainbow trout, oral route is not recommended due to low plasma concentration and bioavailability. However, there is a need to demonstrate the pharmacodynamic activity of tolfenamic acid in rainbow trout.
100 项与 托芬那酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 关节炎 | 中国 | 2005-07-13 | |
| 痛经 | 中国 | 2005-07-13 | |
| 偏头痛 | 中国 | 2005-07-13 | |
| 疼痛 | 中国 | 2005-07-13 | |
| 急性偏头痛 | 丹麦 | 2000-06-06 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 进行性核上性麻痹 | 临床2期 | 美国 |  NeuroTau, Inc.初创企业 | 2021-01-01 |
| 额颞痴呆 | 临床2期 | - | NeuroTau, Inc.初创企业 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 築衊鹹遞淵鹽艱衊願艱(鹹獵獵餘鬱淵網遞選願) = 範餘製獵鬱鑰選築鬱觸 齋壓壓築鏇鏇艱餘廠範 (鑰鏇膚襯艱襯夢壓觸夢 ) | - | 2010-04-15 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用